Amiodarone hyperpigmentation T78.9

Amiodarone (Amiodarex®, Amiohexal®, Cordarex®, Tachydarone®), an iodinated benzofuran derivative, is a potassium antagonist used as a class III antiarrhthmic agent, particularly for supraventricular and ventricular tachycardia. Dermatologic UAWs include slate-gray dyschromias on light-exposed skin areas.

0.5-10% of patients treated with amiodarone show dose-dependent discoloration. 0.1-0.3% of patients develop full vision.

Usually long latency period of at least 10-12 months between first use of amiodarone and appearance of initial symptoms. Initial erythema in about 30-40% of patients, especially on the face. Later, blue or gray dyschromia in light-exposed areas. Skin folds and furrows are usually excluded.

Plaque-like, perivascular conglomerates of yellow-brown color complexes (lipofuscin) in the upper dermis. The "degeneration pigment" lipofuscin, a protein and cholesterol containing mixture of lipophilic and argentophilic pigments and is taken up by lyosomes and histiocytes. Extracellular pigment does not occur.

1. Dereure O (2001) Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2: 253-262.
2. Dissemond J et al (2003) Hyperpigmentation of the face. Dermatologist 54: 994-998
3. Drosner M, Worret WI, Marquart KH (1990) Amiodarone hyperpigmentation. Akt Dermatol 16: 67-69
4. Korting HC, Kolz R, Schmoeckel C, Balda BR (1981) Amiodarone pigmentation. A rare but typical drug side effect. Dermatologist 32: 301-305
5. Levine N (2004) Grayish discoloration in symmetrical pattern on hands. Drug used for cardiac condition may produce skin problem. Geriatrics 59: 32
6. Murphy RP, Canavan M. Skin discoloration from Amiodarone. N Engl J Med. 2020 Jan 16;382(3):e5.
7. Vestesaeger M, Gillot G, Rasson G (1967) Etude clinique d'une nouvelle medication anti-angoreuse. Acta Cardiol 22: 483-500